Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drug developer Human Genome Sciences
So what: Next week, a panel will meet to recommend to the Food and Drug Administration whether Benlysta -- developed by Human Genome along with partner GlaxoSmithKline
Now what: There's no doubt that the Benlysta case is high stakes for Human Genome -- not to mention Glaxo. Bloomberg recently estimated that the drug could bring in more than $2.1 billion in sales by 2014, and its approval could spark takeover offers for Human Genome from Glaxo, along with other giants like Amgen
Want to keep up to date on Human Genome Sciences? Add it to your watchlist by clicking here. Or are you following Benlysta from the Glaxo side? Go ahead and put Glaxo on your watchlist by clicking here.
GlaxoSmithKline is a Motley Fool Global Gains recommendation. Johnson & Johnson is a Motley Fool Income Investor selection. The Fool owns shares of and has written covered calls on GlaxoSmithKline. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer owns shares of Johnson & Johnson and Abbott Labs, but does not own shares of any of the other companies mentioned. You can check out what Matt is keeping an eye on by visiting his Motley Fool CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy assures you no Wookiees were harmed in the making of this article.